ANDA 200151, held by Teva Pharms USA. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 200151 (Selfemra), held by Teva Pharms USA, was first approved by FDA on Feb 3, 2014, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 3, 2014 | Original application | Approved | None posted |
| SelfemraEQ 10MG BASE · tablet;oral | Fluoxetine Hydrochloride | Discontinued |
| SelfemraEQ 15MG BASE · tablet;oral | Fluoxetine Hydrochloride | Discontinued |
| SelfemraEQ 20MG BASE · tablet;oral | Fluoxetine Hydrochloride | Discontinued |
| Aug 18, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 9, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 21, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 20, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 21, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 18, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 3, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters